

孙诗琪,刘路,胡二元,等. 基于小鼠粪菌移植临床前研究影响因素的讨论 [J]. 中国实验动物学报, 2024, 32(1): 100-117.
SUN S Q, LIU L, HU S Y, et al. Discussion of factors influencing preclinical studies based on fecal bacteria transplantation in mice [J]. Acta Lab Anim Sci Sin, 2024, 32(1): 100-117.
Doi:10.3969/j.issn.1005-4847.2024.01.013

基于小鼠粪菌移植临床前研究影响因素的讨论

孙诗琪¹,刘路¹,胡二元¹,王雨岩¹,孙铭声¹,赵凌^{1,2*}

(1. 成都中医药大学针灸推拿学院,成都 610075;2. 针灸治疗老年病教育部
重点实验室(成都中医药大学),成都 610075)

【摘要】 粪菌移植(fecal microbiota transplant,FMT)是一种以肠道微生物为靶向,通过将供体的粪便微生物移植到受体的胃肠道,以重构受体肠道菌群的治疗方式。但 FMT 应对不同疾病的作用机制及不良反应尚未明确,因而无法广泛应用于临床,仍需依赖临床前研究的深入。介于当前报道中实验细节高度不一致或不完整,加之缺乏权威的标准及建议,不仅严重影响了其研究结果的解释和实验过程的复制,同时阻碍了成果的临床转化。本文回顾并讨论了受体选择及移植样本收集、储存、移植材料制备、移植途径等关键步骤,以期能提高实验动物、耗材及劳动力等因素的利用率,为实现 FMT 临床前研究的可复制及标准化提供方法学建议与参考。

【关键词】 小鼠;粪菌移植;方法学;肠道微生物;抗生素

【中图分类号】 Q95-33 **【文献标志码】** A **【文章编号】** 1005-4847 (2024) 01-0100-18

Discussion of factors influencing preclinical studies based on fecal bacteria transplantation in mice

SUN Shiqi¹, LIU Lu¹, HU Shuangyuan¹, WANG Yuyan¹, SUN Mingsheng¹, ZHAO Ling^{1,2*}

(1. Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China;
2. Key Laboratory of Acupuncture for Senile Disease (Chengdu University of TCM), Ministry of Education,
Chengdu 610075, China)

Corresponding author: ZHAO Ling. E-mail: zhaoling@cdutcm.edu.cn

【Abstract】 Fecal microbiota transplantation (FMT) is a therapeutic approach that targets intestinal microorganisms by transplanting fecal microorganisms from healthy individuals into the gastrointestinal tract of diseased individuals, thus restoring the recipient's disordered gastrointestinal microbiota by restructuring the intestinal flora. However, the mechanism of action and adverse effects of FMT in different diseases have not yet been clarified, thus limiting its wide clinical application. Its use still relies on in-depth preclinical studies; however, highly inconsistent or incomplete experimental details provided in current reports, coupled with a lack of authoritative standards and recommendations, seriously affect the interpretation of the study findings and replication of the experimental procedures, as well as hindering the clinical translation of the result. We therefore review and discuss the key steps of recipient selection and graft sample collection, storage, graft material preparation, and grafting route, with the aim of improving the utilization of experimental animals, consumables, and labor, and providing methodological recommendations and references to achieve replicability and standardization of preclinical FMT studies.

【Keywords】 mice; fecal transplants; methodology; gut microbiology; antibiotics

Conflicts of Interest: The authors declare no conflict of interest.

【基金项目】 国家自然科学基金(82274664,82004486)。

Funded by National Natural Science Foundation of China (82274664,82004486).

【作者简介】 孙诗琪,女,在读硕士研究生,研究方向:针灸治疗疼痛疾病研究。Email: sunshiqi@stu.cdutcm.edu.cn

【通信作者】 赵凌,女,博士,研究员,教授,博士生导师,研究方向:针灸治疗疼痛疾病研究。Email: zhaoling@cdutcm.edu.cn

近年来,肠道微生物在健康和疾病中的作用成为热点,其中粪便微生物移植,即粪菌移植(fecal microbiota transplant, FMT),是一种以肠道微生物为靶向,通过将供体粪菌移植到受体胃肠道,以重构受体肠道菌群的治疗方式^[1]。大量研究表明 FMT 不仅在治疗溃疡性结肠炎^[2]、肠易激综合症^[3]等肠道疾病中作用显著,且对包括神经系统疾病(包括脊髓损伤^[4]、阿尔茨海默症^[5])、代谢性疾病(肥胖症^[6]、糖尿病^[7])等因肠道菌群紊乱引起的肠道外疾病同样具有治疗价值。FMT 将肠道微生物变化与病理联系起来,为疾病的治疗及深入研究提供了新的思路和手段。但 FMT 应对不同疾病的作用机制及不良反应尚未明确,因而无法广泛应用于临床试验中,仍需依赖临床前研究的深入。当前报道的 FMT 临床前研究中实验细节高度不一致或不完整,严重影响了其研究的可重复性和结果解释,阻碍了成果的临床转化。本综述从 FMT 常用的小鼠受体着手,对其中包括受体选择、饲养环境、抗生素使用、样本采集及储存条件、移植材料制备、移植途径等在内的关键影响因素进行了讨论,并对不同选择的优势及局限性进行分析。上述影响因素的繁杂性提示亟需提供 FMT 临床前研究标准化实验指导以减少异质性及非必要损耗、提升严谨性及可复制性的必要性。本文回顾并分析近年的相关报道,从 FMT 动物实验的关键步骤及重要影响因素着手,提出针对实现其研究可复制及标准化的建议,并对未来的研究提出展望。

1 受体动物选择

1.1 不同品种及特征受体差异

啮齿动物由于生理解剖结构与人类相似,被广泛应用于临床前研究。得益于肠道微生物在属水平与人类的相似性,小鼠被广泛应用于 FMT 的相关研究,尽管其丰度存在差异^[8-9],但研究人员在小鼠中发现了与人类相似的肠型,且不同菌株丰度差异导致的疾病表现与人类研究中结果一致,为小鼠在 FMT 临床前研究中的应用提供了更多的可能^[10]。LLEAL 等^[11]在评估小鼠和大鼠作为人类微生物移植临床前模型的性能时发现,较小鼠而言,大鼠的肠道环境表现出与人类更高的相似性,且大鼠捕获人类肠道微生物的效率更高,未来或能成为日后建立人源化肠道微生物模型的重要工具。但当前, FMT 的基础研究仍以小鼠为主,大鼠的使用仍有待

更多研究的认可。除品系外,设计 FMT 实验时还需考虑性别、年龄等影响因素,以确保实验结果在不同性别、年龄中都能得到解释。研究表明,肠道微生物状态因性别及年龄而异,其丰度在不同性别受体中不尽相同^[12], FMT 疗效也受受体年龄的影响^[13-15]。综上所述,受体的选择需要依据研究目的选择最相适的品种及特征。

1.2 受体肠道微生物控制途径

1.2.1 选择无菌动物或无特定病原体动物限制常驻微生物

无菌(germ-free, GF)物由于缺乏常驻肠道微生物,在接收外源性肠道微生物时无须竞争,表现出对供体微生物的高效“吸收”,因而 GF 动物被认为是该领域的最佳受体模型^[16-17]。但 GF 状态会导致小鼠的异常发育或生理性改变,如:免疫及代谢系统异常、神经系统异常等^[18-20];如选择 GF 模型则需要考虑规避其特异性改变对目标疾病的影响(表 1)。同时,GF 动物在运输、饲养及处理中对成本投入、环境设施的高要求限制了其广泛应用,加之人类不存在等效的无菌状态,因此使用 GF 动物的研究从临床前向临床的转化存在尚待解释的环节。常规无特定病原体(specific pathogen free, SPF)动物,即指不携带潜在感染或条件致病的病原体的实验动物。与 GF 动物的无菌饲养不同,SPF 动物肠道菌群易受出生及成长环境的影响,通过对 GF 与 SPF 模型疾病表征异同的比较,能够分析常驻肠道微生物对疾病的影响,更能进一步聚焦其中单菌或多菌的具体作用。简化肠道微生物动物亦属于悉生动物,如被报道的最小微生物群落(OligoMM12)小鼠或谢德勒菌群 ASF(Altered Schaedler Flora)模型,作为含有明确微生物的受体模型,能实现对肠道微生物的更准确把控^[21-22]。综上,可选择单独通风笼(Individual ventilated caging, IVC)系统在降低无菌饲养对环境设施及成本的双重高要求的同时实现对菌群一定程度的控制^[23]。针对 GF 动物存在的特异性改变,或能通过 ex-GF 鼠,即出生后立即饲养于微生物充足但无病原体环境的鼠作为对照,以提供由于先天因素对研究结果产生影响的证据。

1.2.2 抗生素预处理消耗肠道微生物

通过抗生素预处理破坏菌群,有操作简单、成本低、环境及设施要求低、可控性强的优势,是当前普遍采用的诱导肠道微生物消耗的有效方法。抗生素预处理不仅能实现 FMT 前的肠道清理^[24],还

表 1 不同受体动物模型间比较

Table 1 Comparison between different receptor animal models		
动物模型 Animal models	优势 Advantages	劣势 Disadvantages
悉生动物动物 Gnotobiotic animals	肠道微生物状态可控；无常驻微生物相竞争；最适宜的粪菌移植临床前实验模型 Gut microbial status can be controlled. No resident microorganisms to compete. Optimal preclinical experimental model for fecal bacteria transplantation	成本投入高；操作及环境、设施要求高；人类不存在等效的无菌状态 High-cost inputs. High operational, environmental and facility requirements. Equivalent sterility does not exist in humans
无病原体动物 Specific pathogen free animals	无特异病原体 No specific pathogen	排出病原体清单或不一致；存在与常驻微生物的竞争 List of excluded pathogens or inconsistencies. Presence of competition with resident microorganisms
抗生素预处理动物 Antibiotic pre-treated animals	在常规环境出生、成长,模型可复制；成本可控 Born and raised in a conventional environment, the model can be replicated. Cost-controllable	抗生素使用存在不良影响；可根据不同研究目的进行选择 Antibiotic use has adverse effects. Can be selected for different research purposes
泻药耗尽动物 Laxative pre-treated animals	与人类临床肠道微生物耗尽途径相当 Comparable to human clinical gut microbial depletion pathways	可参考信息缺乏；泻药使用不良影响未可知 Lack of referable information. Adverse effects of laxative not known

能有效增强异体微生物的定殖能力^[25]。但研究者对携带不同微生物的实验动物进行抗生素预处理后,表现出抗生素扰动后菌群的个体间变异^[26];并在不同抗生素单独使用后观察到对特定类别微生物的特异性改变^[27-28],提示不同抗生素及不同受体在肠道微生物消耗过程中存在个性化差异,建议选择由多种抗生素混合的抗生素鸡尾酒以实现肠道微生物的有效消除。另有研究表明,使用抗生素将促生耐抗生素菌株,并增强病原体的肠道定植力,提升炎症及感染风险^[29];部分抗生素使用存在毒性反应,包括诱发心血管疾病^[30]、破坏血脑屏障^[31],甚至诱发认知障碍^[32]等。因此建议使用被报道的不可吸收的抗生素,以规避由抗生素使用造成的额外影响^[33],如若目标疾病存在使用抗生素无法规避的影响,则考虑采用其他替代方法^[34]。此外,据报道,给药 7 d 足以在保证受体肠道微生物耗尽的同时避免耐抗生素菌的过度生长或耐药性的产生^[35-36],但不排除部分研究为保证微生物的彻底清除而选择了更长的给药时间。在给药方式中,口服灌胃能更好的控制给药剂量及时间,但单次给药能维持的抗生素作用时间有限;饮用水给药虽能长时间维持药效,但难以确保摄入药品的剂量,需刻意记录其饮水量以估算每日摄入抗生素剂量,不适于群居动物,还需要考虑抗生素在饮用水中的放置时间与稳定性^[37-39]。

基于上述的影响因素,研究人员提出建议:(1)在抗生素选择方面建议选用被报道的不可吸收的抗生素类型,以规避抗生素对模型动物造成的额外影响,并以抗生素鸡尾酒的形式配置,以涵盖更广

泛的目标微生物;从整理的结果来看,氨苄西林、新霉素、甲硝唑及万古霉素的组合是最广泛使用的;(2)建议采取间断重复灌胃为主,饮用水添加抗生素维持为辅的给药方式,在保证抗生素摄入量的同时延长抗生素作用时间,以更彻底的清除肠道微生物;(3)给药时间建议保持在 7 ~ 10 d,在有效清除肠道微生物的同时尽可能避免产生抗生素毒性。由于当前不同报道中抗生素给药类型、给药方式、持续时间及剂量等存在差异,基于上述建议研究人员整理了当前高质量报道中抗生素使用的配方及细则,以期为后续研究者提供参考(见表 2)。

1. 2. 3 其他替代方式

肠道清洁溶液 (bowel cleansing, BC) 是临床肠道检查常用的肠道清洁方法,但研究发现 BC 溶液使用后,小鼠肠道微生物群同未处理小鼠一样维持原始状态,且异体微生物的定殖效率不及抗生素制备的肠道环境^[92];又或微生物群的结构和组成在短期内发生变化,但迅速恢复了初始状态^[93]。尽管并不建议使用这样的处理方式,但在抗生素不适用情况下 BC 溶液可作为替代方法,或与抗生素联合使用以增强对肠道微生物的清除效果^[94]。人源化菌群模型是通过移植人类患者的菌群到受体动物,使受体动物携带大部分的人类肠道微生物,以表现出一种或多种疾病特征,模拟疾病发病状态。该模型是药物筛选或疾病发病机制等需要模拟还原疾病状态人类肠道环境研究的重要工具^[95]。研究表明,当前仅约 47% 的人类肠道菌群可以在小鼠中重建,其中超过 1/3 发生显著改变^[16];FMT 的疗效因跨物种移植中外源性微生物定植受阻而减弱^[34],人类

表 2 抗生素肠道预处理方案细则

Table 2 Details of the antibiotic enteral pretreatment program

天数 Days	抗生素鸡尾酒配方 Antibiotic cocktail prescription	饮用水中抗生素配比 Antibiotic rationing in drinking water
3 d ^[40]	10 mg/mL 甲硝唑 + 5 mg/mL 万古霉素 10 mg/mL Metronidazole + 5 mg/mL Vancomycin	1 g/L 氨苄西林 + 0.5 g/L 新霉素 1 g/L Ampicillin + 0.5 g/L Neomycin
3 d ^[41] 、 5 d ^[42-45] 、 7 d ^[46-47]	0.2 g/kg 氨苄西林 + 0.2 g/kg 新霉素 + 0.2 g/kg 甲硝唑 + 0.1 g/kg 万古霉素 0.2 g/kg Ampicillin + 0.2 g/kg Neomycin + 0.2 g/kg Metronidazole + 0.1 g/kg Vancomycin	- - -
5 d ^[48]	10 g/L 新霉素 + 10 g/L 甲硝唑 + 5 g/L 青霉素 10 g/L Neomycin + 10 g/L Metronidazole + 5 g/L Penicillin	1 g/L 氨苄西林 1 g/L Ampicillin
3 d ^[49]	1 g/L 氨苄西林 + 10 g/L 新霉素 + 10 g/L 甲硝唑 + 5 g/L 万古霉素 1 g/L Ampicillin + 10 g/L Neomycin + 10 g/L Metronidazole + 5 g/L Vancomycin	-
5 d ^[50]	2 g/L 氨苄西林 + 1 g/L 新霉素 + 2 g/L 甲硝唑 + 1 g/L 万古霉素 2 g/L Ampicillin + 1 g/L Neomycin + 2 g/L Metronidazole + 1 g/L Vancomycin	-
3 d ^[51-52] 、 5 d ^[53] 、 7 d ^[54] 、 14 d ^[55]	1 g/L 氨苄西林 + 0.5 g/L 新霉素 + 1 g/L 甲硝唑 + 0.5 g/L 万古霉素 1 g/L Ampicillin + 0.5 g/L Neomycin + 1 g/L Metronidazole + 0.5 g/L Vancomycin	- - - 与抗生素鸡尾酒相同配比 Same ratio as antibiotic cocktail
7 d ^[56] 、 7 d ^[57] 、 10 d ^[58] 、 21 d ^[59-60] 、 28 d ^[61] 、 28 d ^[62-64]	1 g/L 氨苄西林 + 1 g/L 新霉素 + 1 g/L 甲硝唑 + 0.5 g/L 万古霉素 1 g/L Ampicillin + 1 g/L Neomycin + 1 g/L Metronidazole + 0.5 g/L Vancomycin	- - 200 mg/L 链霉素 200 mg/L Streptomycin 饮用水替代口服 Antibiotic drinking water alternative to oral
14 d ^[65]	1 g/L 氨苄西林 + 1 g/L 新霉素 + 1 g/L 甲硝唑 + 10 g/L 万古霉素 1 g/L Ampicillin + 1 g/L Neomycin + 1 g/L Metronidazole + 10 g/L Vancomycin	0.5 g/L 万古霉素 0.5 g/L Vancomycin
3 d ^[66]	0.25 g/L 新霉素 + 0.25 g/L 甲硝唑 + 0.25 g/L 万古霉素 0.25 g/L Neomycin + 0.25 g/L Metronidazole + 0.25 g/L Vancomycin	饮用水替代口服 Antibiotic drinking water alternative to oral
3 d ^[67]	1 g/L 氨苄西林 + 5 g/L 链霉素 + 1 g/L 粘菌素 1 g/L Ampicillin + 5 g/L Streptomycin + 1 g/L Colistin	饮用水替代口服 Antibiotic drinking water alternative to oral
3 d ^[68]	1 g/L 氨苄西林 + 5 g/L 新霉素 + 1 g/L 粘菌素 + 0.25 g/L 万古霉素 1 g/L Ampicillin + 5 g/L Neomycin + 1 g/L Colistin + 0.25 g/L Vancomycin	饮用水替代口服 Antibiotic drinking water alternative to oral
5 d ^[69]	100 mg/kg 新霉素 + 25 mg/kg 多粘菌素 B 100 mg/kg Neomycin + 25 mg/kg Polymyxin B	饮用水替代口服 Antibiotic drinking water alternative to oral
5 d ^[70]	300 mg/kg 氨苄西林 + 300 mg/kg 诺氟沙星 300 mg/kg Ampicillin + 300 mg/kg Norfloxacin	-
5 d ^[71]	0.1% (w/v) 杆菌肽 + 0.05% (w/v) 万古霉素 0.1% (w/v) Bacitracin + 0.05% (w/v) Vancomycin	-
7 d ^[72]	1 g/L 甲硝唑 + 1 g/L 万古霉素 + 2 g/L 链霉素 1 g/L Metronidazole + 1 g/L Vancomycin + 2 g/L Streptomycin	-
7 d ^[73]	50 mg/kg 万古霉素 + 100 mg/kg 新霉素 + 100 mg/kg 甲硝唑 50 mg/kg Vancomycin + 100 mg/kg Neomycin + 100 mg/kg Metronidazole	1 g/L 氨苄西林 1 g/L Ampicillin
7 d ^[74]	50 mg/kg 万古霉素 + 100 mg/kg 新霉素 + 100 mg/kg 甲硝唑 + 1 mg/kg 两性霉素 B 50 mg/kg Vancomycin + 100 mg/kg Neomycin + 100 mg/kg Metronidazole + 1 mg/kg Amphotericin B	1 g/L 氨苄西林 1 g/L Ampicillin

续表 2

天数 Days	抗生素鸡尾酒配方 Antibiotic cocktail prescription	饮水中抗生素配比 Antibiotic rationing in drinking water
7 d ^[75]	1 g/L 氨苄西林 + 1 g/L 新霉素 + 1 g/L 甲硝唑 + 0.5 g/L 万古霉素 + 2.5 mg/L 两性霉素 B 1 g/L Ampicillin + 1 g/L Neomycin + 1 g/L Metronidazole + 0.5 g/L Vancomycin + 2.5 mg/L Amphotericin B	—
10 d ^[76]	1 g 氨苄西林 + 0.5 g/kg 新霉素 + 0.1 g/kg 庆大霉素 + 0.5 g/kg 万古霉素 + 10 mg/kg 红霉素 1 g Ampicillin + 0.5 g/kg Neomycin + 0.1 g/kg Gentamicin + 0.5 g/kg Vancomycin + 10 mg/kg Erythromycin	饮用水替代口服 Antibiotic drinking water alternative to oral
10 d ^[77]	0.5 g/L 氨苄西林 + 0.5 g/L 新霉素 + 0.5 g/L 甲硝唑 + 0.25 g/L 万古霉素 0.5 g/L Ampicillin + 0.5 g/L Neomycin + 0.5 g/L Metronidazole + 0.25 g/L Vancomycin	饮用水替代口服 Antibiotic drinking water alternative to oral
10 d ^[78]	2 g/L 氨苄西林 + 2 g/L 新霉素 + 2 g/L 甲硝唑 + 1 g/L 万古霉素 + 2 g/L 庆大霉素 2 g/L Ampicillin + 2 g/L Neomycin + 2 g/L Metronidazole + 1 g/L Vancomycin + 2 g/L Gentamicin	—
14 d ^[79]	1 g/L 氨苄西林 + 1 g/L 新霉素 + 1 g/L 甲硝唑 + 0.25 g/L 万古霉素 1 g/L Ampicillin + 1 g/L Neomycin + 1 g/L Metronidazole + 0.25 g/L Vancomycin	饮用水替代口服 Antibiotic drinking water alternative to oral
14 d ^[80]	0.1 g/L 氨苄西林 + 1 g/L 新霉素 + 1 g/L 甲硝唑 + 0.5 g/L 万古霉素 0.1 g/L Ampicillin + 1 g/L Neomycin + 1 g/L Metronidazole + 0.5 g/L Vancomycin	饮用水替代口服 Antibiotic drinking water alternative to oral
14 d ^[81]	0.5 g/L 新霉素 + 0.5 g/L 万古霉素 + 0.5 g/L 西司他丁 0.5 g/L Neomycin + 0.5 g/L Vancomycin + 0.5 g/L Cilastatin	—
14 d ^[82]	20 g/L 氨苄西林 + 20 g/L 新霉素 + 20 g/L 甲硝唑 + 10 g/L 万古霉素 20 g/L Ampicillin + 20 g/L Neomycin + 20 g/L Metronidazole + 10 g/L Vancomycin	—
14 d ^[83]	250 mg/L 万古霉素 + 200 mg/L 链霉素 250 mg/L Vancomycin + 200 mg/L Streptomycin	饮用水替代口服 Antibiotic drinking water alternative to oral
14 d ^[84]	1 g/L 氨苄西林 + 0.5 g/L 新霉素 1 g/L Ampicillin + 0.5 g/L Neomycin	饮用水替代口服 Antibiotic drinking water alternative to oral
16 d ^[85]	250 mg/mL 杆菌肽 + 170 mg/mL 庆大霉素 + 125 mg/mL 环丙沙星 + 100 mg/mL 新霉素 + 100 mg/mL 甲硝唑 + 100 mg/mL 头孢他啶 + 50 mg/mL 链霉素 + 50 mg/mL 万古霉素 250 mg/mL Bacitracin + 170 mg/mL Gentamicin + 125 mg/mL Ciprofloxacin + 100 mg/mL Neomycin + 100 mg/mL Metronidazole + 100 mg/mL Ceftazidime + 50 mg/mL Streptomycin + 50 mg/mL Vancomycin	饮用水替代口服 Antibiotic drinking water alternative to oral
21 d ^[86]	0.5 g/L 新霉素 + 0.7 g/L 万古霉素 + 0.5 g/L 西司他丁 0.5 g/L Neomycin + 0.7 g/L Vancomycin + 0.5 g/L Cilastatin	饮用水替代口服 Antibiotic drinking water alternative to oral
1 d ^[87]	975 mg/kg 万古霉素 975 mg/kg Vancomycin	—
28 d ^[88]	0.5 g/L 万古霉素 0.5 g/L Vancomycin	—
32 d ^[89]	100 mg/kg 氨苄西林 + 100 mg/kg 新霉素 + 100 mg/kg 甲硝唑 + 10 mg/kg 两性霉素 B 100 mg/kg Ampicillin + 100 mg/kg Neomycin + 100 mg/kg Metronidazole + 10 mg/kg Amphotericin B	饮用水替代口服 Antibiotic drinking water alternative to oral
全程 ^[90] Whole process	1 g/L 氨苄西林 + 1 g/L 大肠杆菌素 + 5 g/L 链霉素 1 g/L Ampicillin + 1 g/L Colicin + 5 g/L Streptomycin	—
全程 ^[91] Whole process	1 g/L 氨苄西林 + 0.5 g/L 新霉素 1 g/L Ampicillin + 0.5 g/L Neomycin	饮用水替代口服 Antibiotic drinking water alternative to oral

肠道环境在啮齿动物中的完整重建仍有待后续研究的深入,如需选择该模型则应当明确是否需要建立对照以对跨物种移植产生的紊乱作出合理解释。

1.3 饮食及环境对肠道微生物的影响

肠道微生物的组成和比例是动态的,同时受内部(年龄和遗传背景)和外部(饮食和环境)因素的影响^[96-97]。通过控制饮食摄入及环境温度可以诱导能量消耗、肠道菌群及代谢物的改变^[98-101]。基于饮食-环境-微生物群间相互作用的复杂性,研究者在使用相同饮食方案但光暗周期及环境温度不同的啮齿动物中观察到肠道微生物组成的显著差异,并在每日明暗循环及季节变化中观察到肠道微生物的规律性改变^[102-103]。因此可考虑使用时间限制喂养(TRF)将饮食摄入控制在 24 h 周期的特定时间内,避免生物钟改变对肠道菌群的影响^[104]。此外,由于啮齿类动物具有食粪习性,研究发现同笼饲养几周后,微生物相关表型能够在共同安置的小鼠间转移,因而要避免将准备接受来自不同组别供体的受体置于同一饲养区域^[105]。未来的 FMT 临床前研究当谨慎选择并在报告中交代实验动物所接受的饮食、环境(如温度、湿度以及明/暗循环),以完整解释饮食或环境因素对结果的影响。

2 移植前操作

2.1 样本收集及储存的建议

采集粪便样本时建议先用 75% 乙醇消毒啮齿动物肛门,然后用无菌棉球轻压肛门同时按揉腹部,引起自发排便后立即将粪便颗粒转移到冰上的无菌离心管或冻存管中;如果无法诱导即时排便可以将供体动物转移到高压灭菌笼或已消毒的独立环境中,待其自然排便后再立即收集^[106-109]。啮齿动物供体样本除粪便外还可能涉及肠腔内容物,可待动物麻醉后直接在厌氧无菌条件下采集^[110]。相较于局部内容物而言全肠菌群移植(Whole-intestinal microbiota transplantation, WIMT)能够相对完整的重建整个胃肠道环境^[111],且来自特定位置的微生物能够选择性地定殖到同源区域,因此当需要重建整个胃肠道微生物状态或对肠道不同区域微生物进行靶向分析、干预时 WIMT 可作为最佳选择。上述空间异质性提示胃肠道中不同部分间微生物不可相互替代,且其组成及丰度存在差异,据报道,与空肠和回肠相比,盲肠、结肠和粪便中的微生物含量更高,因而多被选择^[112]。在采集时间上,

基于报道的啮齿动物 24 h 内肠道微生物丰度变化规律,建议在 7:00 ~ 11:00 或 15:00 ~ 17:00 进行,以避免昼夜节律影响样本成分的稳定性^[112-113]。

研究表明哺乳动物肠道内多数微生物属于厌氧菌,在氧气中暴露将使这些菌群失去活性^[114],为最大限度保留微生物活性,粪便样本的采集及匀质化、过滤等操作需要在厌氧条件下进行。粪便的采集难以在绝对厌氧的环境中进行,因此建议使用厌氧袋或在装有二氧化碳的开放式容器中进行的半厌氧处理法。若采集肠腔内容物则可当动物处死后在厌氧室内进行,并使用脱氧溶液进行稀释和均质。

低温冻存是保持粪便样本中微生物组成及丰度的有效方式,样本在采集后及运输过程中需保持 4 °C 或临时冰上保存,短期保存时 -20 °C 可以实现对其中微生物定殖能力的保护,如需冻存超过 6 个月则需要 -80 °C 储存,以保证定植能力不受影响^[115-117],但理想模式是采集后 1 h 内制备并立即移植^[118]。需要强调的是,冻融循环比持续长时间冻存更伤害微生物活性,如不能持续低温冻存,可以暂存于较低温环境,避免反复的冻融循环。样本长期零度以下储存时需添加冷冻保护剂(cryoprotectants, CPA),如 15% 或 20% (v/v) 甘油及 5% (v/v) 二甲基亚砷或麦芽糊精与海藻糖混合物(1:3)等^[119],以减少冻融环节对细胞的损伤,并保持冻存样本的菌株活性^[120]。此外,冻干样品能更大限度保持微生物稳定性^[121],粪便等分吸管技术(Fecal Aliquot Straw Technique, FAST)能实现不解冻情况下的二次取样^[122-123],研究者可持续关注新报道的方法以选择成本及设施范围内的最佳储存方案。

2.2 移植材料制备的建议

制备移植材料时样本需先稀释并过滤后,再按照比例悬浮在磷酸缓冲盐溶液(phosphate buffered saline, PBS)中静置沉淀,然后以预设参数反复离心^[124-127],制备完成后应立即进行移植(图 1)。为避免微生物成分在移植前发生改变,建议在移植前 10 min 临时制备移植材料,以保证最短的氧气暴露时间。如果不具备新鲜制备条件,可以将新鲜样本立即制成移植材料然后低温冻存,至使用时再解冻^[126]。本文回顾了近年的相关研究,在移植材料的制备过程中尽管具体配置比例及离心参数有所不同,但大致步骤相似,研究人员总结了其中相对完整的操作方案以供参考(表 3)。

表 3 粪菌移植前关键操作细则

Table 3 Details of key operations before fecal bacteria transplantation

移植材料制备 Transplantation material preparation	移植方式 Transplantation method	参考文献 Reference
样本在 600 μL 还原 PBS(含 0.5 g/L 半胱氨酸和 0.2 g/L 硫化钠) 中匀质, 通过 70 μm 细胞过滤器过滤 Samples were resuspended with a vortex in 600 μL of reduced PBS (PBS with 0.5 g/L cysteine and 0.2 g/L Na ₂ S) and then filtered through a 70 μm cell strainer	2 周: 每次 100 μL, 每周 3 次 2 周后: 每周 1 次 2 weeks: 100 μL each time, 3 times per week After 2 weeks: 1 time per week	[53]
100 mg 样本在 1 mL 无菌盐水(含 0.5 g/L 半胱氨酸) 中稀释, 混合物以 1000 r/min 离心 1 min 100 mg of samples diluted in 1 mL sterile saline (with 0.5 g/L cysteine), the fecal slurry was centrifuged at 1000 r/min for 1 min	8 周: 每次 200 μL 8 weeks: 200 μL each time	[82]
200 mg 样本在 1 mL PBS(含 0.5 g/L 半胱氨酸和 0.2 g/L 硫化钠) 中混悬, 通过 40 μm 细胞过滤器后, 混合物以 500 × g 离心 1 min 新鲜制备 200 mg of samples were resuspended with a vortex in 1 mL of reduced PBS (with 0.5 g/L cysteine and 0.2 g/L Na ₂ S) and then filtered through a 40 μm cell strainer, the fecal slurry was centrifuged at 500 × g for 1 min Freshly prepared	4 周: 每次 100 μL, 每周 2 次 4 周后: 每周 1 次 4 weeks: 100 μL each time, 2 times per week After 4 weeks: 1 time per week	[50]
500 mg 样本在 PBS(含 2.5 mg 半胱氨酸及 1 mg 硫化钠) 中混悬, 混合物以 500 r/min 离心 500 mg of samples were resuspended with a vortex in PBS (With 2.5 mg cysteine and 1 mg Na ₂ S) and then centrifuged at 500 r/min	2 周: 每次 100 μL, 每天 1 次 2 weeks: 100 μL each time, once a day	[128]
样本在 1 mL PBS(含 0.05% 半胱氨酸) 中冰上稀释并匀质, 混合液以 4 ℃, 3000 × g 离心 5 min, 分离上清液 Samples were diluted in 1 mL PBS (with 0.05% cysteine) on ice and homogenized, and then centrifuged at 4 ℃, 3000 × g for 5 min to obtain fecal supernatant	2 周: 每次 200 μL, 每周 3 次 2 weeks: 200 μL each time, 3 times per week	[129]
粪便样本通过 100 μm 细胞过滤器过滤 Fecal samples were filtered through a 100 μm cell strainer	—	[85]
粪便样本通过 100 μm 细胞过滤器过滤 25% PBS 混合-80 ℃冻存 Fecal samples were filtered through a 100 μm cell strainer Mix with 25% PBS and freeze at -80 ℃	每次 200 μL, 每周 2 次 100 μL each time, 2 times per week	[86]
样本在 10 mL 无菌 PBS 中稀释并匀质, 混合液通过一次性注射器过滤 Samples were diluted in 10 mL of sterile PBS and then filtered through a disposable syringe filtration	3 周: 每次 200 μL, 每周 1 次 3 weeks: 200 μL each time, once per week	[63]
粪便样本与 PBS 混悬, 通过 30 μm 细胞过滤器过滤 Fecal samples were diluted in PBS and filtered through 30 μm cell strainer	3 周: 每周 2 次 3 weeks: 2 times per week	[60]
30 mg 样本在 1 mL PBS 中稀释并匀质, 沉淀 10 min 后, 通过 40 μm 细胞过滤器过滤 10% 甘油混合-80 ℃冻存 30 mg of samples were diluted in 1 mL PBS, and after 10 min of sedimentation, then filtered through a 40 μm cell strainer Mixed with 10% glycerol and frozen at -80 ℃	8 周: 每次 100 μL, 每周 2 次 8 weeks: 100 μL each time, 2 times per week	[75]
50 mg 样本在 1 mL 无菌盐水中稀释并匀质, 混合液以 100 × g 离心 2 min, 分离上清液, 并通过 30、0.45、0.22 μm 细胞过滤器过滤 50 mg of samples were diluted in 1 mL of sterile saline, and centrifuged at 100 × g for 2 min to obtain supernatant, and filtered through 30, 0.45, 0.22 μm cell strainer	每次 200 μL, 每天 1 次 200 μL each time, once a day	[69]
100 mg 样本在 1 mL PBS 中稀释并匀质, 混合液以 100 × g 离心 2 min, 通过 70 μm 细胞过滤器过滤 100 mg samples were diluted in 1 mL of PBS, and centrifuged at 100 × g for 2 min and then filtered through 70 μm cell strainer	第 1 ~ 3 天: 每次 200 μL, 每天 1 次 第 4 ~ 11 天: 每次 200 μL, 2 d 1 次 Day 1 ~ 3: 200 μL each time, once a day Day 4 ~ 11: 200 μL each time, once every two days.	[52]

续表 3

移植材料制备 Transplantation material preparation	移植方式 Transplantation method	参考文献 Reference
50 mg 样本在 1mL PBS 中稀释并匀质,以 100 × g 离心 2 min,通过 70 μm 细胞过滤器过滤 50 mg fecal samples were diluted in 1 mL PBS, and centrifuged at 100 × g for 2 min and then filtered through 70 μm cell strainer	1 周:每次 100 μL,每天 1 次 1 week: 100 μL each time, once a day	[130]
100 mg 样本在无菌 PBS 中浸泡 15 min,混合液通过 70 μm 细胞过滤器过滤,以 4 ℃ 离心 5 min 100 mg of samples were soaked in sterile PBS for 15 min, filtered through 70 μm cell strainer, centrifuged at 4 ℃ for 5 min	1 周:10 mL/kg,每天 1 次 1 week: 100 mL/kg, once a day	[79]
样本在冰冷的双蒸水中稀释并匀质(1:50),混合液通过 70 μm 细胞过滤器过滤 Samples were diluted (1:50) in ice-cold double-distilled water, then filtered through 70 μm cell strainer	4 周:每次 200 μL,每 2 h 1 次 连续 3 次 4 weeks: 200 μL each time, every 2 h, three times in a row	[131]
粪便样本在 500 μL PBS 中稀释并匀质 -80 ℃ 冻存 Fecal samples were diluted in 500 μL PBS -80 ℃ frozen	3 d:每次 500 μL 3 d: 500 μL each time	[49]
粪便样本在 800 μL PBS 中稀释并匀质,涡旋 1 min -80 ℃ 冻存 Fecal samples were diluted in 800 μL PBS, vortex 1 min -80 ℃ frozen	每次 200 μL 200 μL each time	[132]
10 mg 粪便样本在 2 mL PBS 中稀释并匀质,涡旋 30 s 10 mg samples were diluted in 2 mL PBS, vortex 30 s	4 周:每次 200 μL,每天 1 次 4 weeks: 200 μL each time, once a day	[70]
50 mg 粪便样本在 1.5 mL PBS 中稀释并匀质 -80 ℃ 冻存 50 mg of fecal samples were diluted in 1.5 mL PBS -80 ℃ frozen	4 周:每次 100 μL,每天 1 次 4 weeks: 100 μL each time, once a day	[64]
100 mg 粪便样本在 1 mL PBS 中稀释并匀质 100 mg of fecal samples were diluted in 1 mL PBS	1 周:每次 200 μL,每天 1 次 1 week: 200 μL each time, once a day	[133]
110 mg 粪便样本在 350 μL PBS 中稀释并匀质 110 mg of fecal samples were diluted in 350 μL PBS	8 周:每次 350 μL 8 weeks: 350 μL each time	[134]
125 mg 粪便样本在 1 mL PBS 中稀释并匀质 20% 甘油混合-80 ℃ 冻存 125 mg of fecal samples were diluted in 1 mL PBS Mixed with 20% glycerol and frozen at -80 ℃	每次 200 μL,每周 3 次 200 μL each time, 3 times per week	[83]
130 ~ 150 mg 样本在 1 mL PBS 中稀释并匀质 130 ~ 150 mg of samples were diluted in 1 mL PBS	2 周:每次 200 μL,每周 1 次 2 weeks: 200 μL each time, once per week	[61]
200 mg 粪便样本在 1.5 mL PBS 中稀释并匀质 200 mg of fecal samples were diluted in 1.5 mL PBS	4 周:每次 100 μL,每周 3 次 4 weeks: 100 μL each time, 3 times per week	[59]
200 mg 粪便样本在 1 mL PBS 中稀释并匀质 200 mg of fecal samples were diluted in 1 mL PBS	第 1 天:每次 200 μL + 直肠灌注 100 μL 24 h 后:每次 200 μL Day 1: 200 μL with each time + Rectal instillation of 100 μL After 24 h: 200 μL each time	[66]
1 g 粪便样本在 5 mL PBS 中稀释 1 g of fecal samples were diluted in 5 mL PBS	每次 200 μL 200 μL each time	[135]
样本在无菌 PBS 中(含 15% 无菌甘油)稀释并匀质 -80 ℃ 冻存-80 ℃ Samples were diluted in sterile PBS (15% sterile glycerol) frozen	5 d:每次 200 μL,2 d 1 次 5 d: 200 μL each time, once every two days.	[136]
粪便样本在 PBS 中(含 20% 无菌甘油)稀释并匀质 5 min Fecal samples were diluted in sterile PBS (containing 20% sterile glycerol) for 5 min	3 d:每次 1 mL,每天 1 次 附加:其余喷洒在住处 3 d: 1 mL each time, once a day Additional: sprayed in the residence	[137]

续表 3

移植材料制备 Transplantation material preparation	移植方式 Transplantation method	参考文献 Reference
1 g 样本在 5 mL 无菌 PBS(含 20% 无菌甘油)中稀释并匀质,混合液离心后分离上清液 -80 ℃ 冻存 1 g of samples were diluted in 5 mL of sterile PBS (containing 15% sterile glycerol), then centrifuged to obtain fecal supernatant -80 ℃ frozen 粪便样本在无菌 PBS(含 50% 无菌甘油)中稀释并匀质 (1:10),混合液使用前 1:5 稀释 -20 ℃ 冻存 Fecal samples were diluted in sterile PBS (containing 50% sterile glycerol) (1:10), mixture diluted 1:5 before use -20 ℃ frozen	1 周:每次 300 μL,每天 1 次 1 week: 300 μL each time, once a day	[138]
粪便样本在 10 mL 无菌生理盐水中稀释并均质 Fecal samples were diluted in 10 mL sterile saline	每次 150 μL,每周 3 次 150 μL each time, 3 times per week	[139]
150 mg 样本在 1 mL 无菌甘油中混合,稀释 5 倍使用 10% 甘油混合-80 ℃ 冻存 150 mg of samples were diluted in 1 mL sterile glycerine, dilute 5 times for use Mixed with 10% glycerol and frozen at -80 ℃	2 周:每次 200 μL,每周 3 次 附加:皮毛涂抹 100 μL 2 weeks: 200 μL each time, 3 times per week Additional: 100 μL applied to the skin	[140]
粪便样本在无菌生理盐水中稀释并匀质 (1:10),混合液以 1000 r/min,4 ℃ 离心 15 min 40% 甘油混合-80 ℃ 冻存 Fecal samples were diluted in sterile saline (1:10), then centrifuge at 1000 r/min for 15 min at 4 ℃ Mixed with 40% glycerol and frozen at -80 ℃	5 d:每次 200 μL,每天 1 次 5 d: 200 μL each time, once a day	[141]
样本在无菌生理盐水中稀释并匀质 (1:10) 1 min,混合液以 500 × g 离心 3 min,分离上清液 移植前 10 min 临时制备 Samples were diluted in sterile saline (1:10) for 1 min, then centrifuge at 500 × g for 3 min to obtain fecal supernatant Prepared 10 min before transplantation	2 周:每次 1 mL,每天 1 次 2 weeks: 1 mL each time, once a day	[43]
样本在无菌生理盐水中稀释并匀质 (1:10) 1 min,混合液以 500 × g 离心 3 min,分离上清液 移植前 10 min 临时制备 Samples were diluted in sterile saline (1:10) for 1 min, then centrifuge at 500 × g for 3 min to obtain fecal supernatant Prepared 10 min before transplantation	每次 200 μL 200 μL each time	[57]
样本在无菌生理盐水中稀释并匀质 (1:10),混合液离心后分离上清液 -80 ℃ 冻存 Samples were diluted in sterile saline (1:10), then centrifuge to obtain fecal supernatant -80 ℃ frozen 样本在无菌 PBS 中稀释并匀质 (1:20),混合液以 4 ℃, 1000 × g 离心 5 min,分离上清液 移植前 10 min 临时制备 Samples were diluted in sterile saline (1:20), centrifuge at 1000 × g for 5 min at 4 ℃ to obtain fecal supernatant Prepared 10 min before transplantation	8 周:每次 200 μL,每周 2 次 8 weeks: 200 μL each time, 2 times per week	[142]
样本在无菌 PBS 中稀释并匀质 (1:20),混合液以 4 ℃, 1000 × g 离心 5 min,分离上清液 移植前 10 min 临时制备 Samples were diluted in sterile saline (1:20), centrifuge at 1000 × g for 5 min at 4 ℃ to obtain fecal supernatant Prepared 10 min before transplantation	2 周:每次 100 μL,每天 1 次 2 weeks: 100 μL each time, once a day	[88]
粪便样本在等体积 PBS 中稀释并匀质,混合离心 Fecal samples were diluted in an equal volume of PBS, then mixed and centrifuged	3 d:每次 100 μL,每天 1 次 附加:皮毛涂抹 100 μL 3 d: 100 μL each time, once a day Additional: 100 μL applied to the skin	[41]
粪便样本在无菌 PBS 中稀释并匀质,混合液以 500 × g 离心 30 s,分离上清液 Fecal samples were diluted in sterile PBS, and centrifuged at 500 × g for 30 s to obtain fecal supernatant	1 周:每次 200 μL,每天 1 次 1 week: 200 μL each time, once a day	[46]
100 mg 粪便样本在无菌 PBS 中稀释并匀质,混合液以 500 × g 离心 5 min 100 mg of samples were diluted in sterile PBS, centrifuged at 500 × g for 5 min	3 周:每次 100 μL,每周 2 次 3 weeks: 100 μL each time, 2 times per week	[143]
100 mg 样本在 2 mL 无菌 PBS 中稀释并匀质,混合液涡旋 3 min,以 4 ℃, 800 × g 离心 3 min 100 mg of samples were diluted in 2 mL of sterile PBS, and vortex 3 min, centrifuged at 800 × g for 3 min at 4 ℃	每次 200 μL,每 2 周 1 次 200 μL each time, once every two weeks	[84]

续表 3

移植材料制备 Transplantation material preparation	移植方式 Transplantation method	参考文献 Reference
100 mg 样本在 1 mL 无菌 PBS 中稀释并匀质 10 min,混合液涡旋 1 min, 以 800 × g 离心 5 min -80 ℃冻存 100 mg of samples were diluted in 1 mL of sterile PBS for 10 min, and vortex 1 min, centrifuged at 800 × g for 5 min -80 ℃ frozen	每次 1 mL,每天 1 次 1 mL each time, once a day	[74]
100 mg 粪便样本在 1 mL 无菌 PBS 中稀释并匀质 5 min , 混合液以 800 × g 离心 3 min 100 mg of fecal samples were diluted in 1 mL of sterile PBS for 5 min, and centrifuged at 800 × g for 3 min	12 周:每次 200 μL,每周 1 次 12 weeks: 200 μL each time, 1 time per week	[144]
100 mg 样本在生理盐水中稀释并匀质,涡旋 1 min,混合液以 500 × g 离心 3 min 移植前 10 min 临时制备 100 mg of samples were diluted in sterile saline, and vortex 1 min, then centrifuged at 500 × g for 3 min Prepared 10 min before transplantation	-	[56]
300 mg 粪便样本在 1 mL 无菌 PBS 中稀释并匀质,混合液以 1500 × g 离心 5 min -80 ℃冻存 300 mg of fecal samples were diluted in 1 mL of sterile PBS, and centrifuged at 1500 × g for 5 min -80 ℃ frozen	4 周:每次 200 μL,2 d 1 次 4 weeks: 200 μL each time, once every two days	[62]
100 mg 样本在 1 mL 无菌生理盐水中稀释 1 min,混合液以 1000 × g 离心 3 min 移植前 10 min 临时制备 100 mg of samples were diluted in 1 mL of sterile saline for 1 min, and centrifuged at 1000 × g for 3 min Prepared 10 min before transplantation	2 周:每次 100 μL,每天 1 次 2 weeks: 100 μL each time, once a day	[145]
5 ~ 6 颗粪便样本在 1 mL 无菌 PBS 中稀释并匀质,混合液 以 4 ℃, 1000 r/min 离心 1 min 5 ~ 6 fecal samples were diluted in 1 mL of sterile PBS, and centrifuged at 1000 r/min for 1 min at 4 ℃	2 周:每次 200 μL,每天 1 次 2 weeks: 200 μL each time, once a day	[73]
200 mg 样本在 1 mL 无菌 PBS 中稀释并匀质,混合液以 1500 r/min 离心 5 min 移植前临时制备 200 mg of samples were diluted in 1 mL of sterile PBS, and centrifuged at 1500 r/min for 5 min Prepared before transplantation	5 d:每次 300 μL,每天 1 次 其余 7 周:每周 1 次 5 d: 300 μL each time, once a day Remaining seven weeks: once a week	[55]
1 g 样本在 15 mL 无菌 PBS 中稀释并匀质,混合液以 3000 r/min 离心 5 min 无菌 20%脱脂牛奶混合冻存 1 g of samples were diluted in 15 mL of sterile PBS, and centrifuged at 3000 r/min for 5 min Aseptic 20% skim milk blend freezing	2 周:每次 200 μL,2 d 1 次 2 weeks: 200 μL each time, once every two days	[77]
10 mg 粪便样本在 1 mL 无菌 PBS 中稀释并匀质,混合液以 4000 r/min , 4 ℃离心 10 min 移植前临时制备 10 mg of fecal samples were diluted in 1 mL of sterile PBS, and centrifuged at 4000 r/min for 10 min at 4 ℃ Prepared before transplantation	-	[146]
样本在脱氧无菌水(0.2 g/mL)中稀释并均质,纱布过滤,5000 × g 离心 5 min , 与脱氧无菌水混悬(0.3 g/mL) 甘油(4:1)混合-80 ℃冻存 Samples were diluted in deoxygenated sterile water (0.2 g/mL) , filtered through gauze and centrifuged at 5000 × g for 5 min, then mixed with deoxygenated sterile water (0.3 g/mL) Mixed with glycerol (4:1) and frozen at -80 ℃	2 周:10 mg/kg,每天 1 次 2 weeks: 10 mg/kg, once a day	[51]
100 mg 粪便样本在 1 mL 无菌生理盐水中稀释并匀质,混合液以 1000 r/min 离心 3 min 移植前 10 min 临时制备 100 mg of fecal samples were diluted in 1 mL of sterile saline for 1 min, and centrifuged at 1000 r/min for 3 min Prepared 10 min before transplantation	1 周:每次 200 μL,每天 1 次 1 week: 200 μL each time, once a day	[147]

续表 3

移植材料制备 Transplantation material preparation	移植方式 Transplantation method	参考文献 Reference
100 ~ 150 mg 粪便样本在 3 mL 无菌生理盐水中稀释匀质 30 s, 混合液重力沉淀 5 min 100 ~ 150 mg of fecal samples were diluted in 3 mL of sterile saline for 30 s, then settled by gravity for 5 min	8 周; 每次 300 μL, 每周 2 次 附加: 其余粪便样本放置于住处 8 weeks: 300 μL each time, 2 times per week Additional: the rest of the fecal samples were placed at the residence	[148]
粪便样本在冰冷生理盐水中稀释并匀质, 涡旋 30 s 并重力沉淀 1 min 移植前 10 min 临时制备 Fecal samples were diluted in ice-cold saline, vortexed for 30 s and settled by gravity for 1 min Prepared 10 min before transplantation	8 周; 每只 10 ⁸ CFU, 每周 2 次 8 weeks: 10 ⁸ CFU per mouse, twice per week	[71]
粪便样本在 1 mL PBS 和 1 mL 脱脂牛奶中稀释并匀质, 混合液重力沉淀 5 min 后 Fecal samples were diluted in 1 mL of PBS and 1 mL of skimmed milk, then settled by gravity for 5 min	2 周; 每次 1 mL, 每天 1 次 2 weeks: 1 mL each time, once a day	[58]
80 ~ 110 mg 样本在 1 mL PBS 中稀释并匀质, 混合液体以 2000 × g 离心 1 min 移植前临时制备 80 ~ 110 mg of samples were diluted in 1mL of sterile PBS, and centrifuged at 2000 × g for 1min Prepared before transplantation	第 1 周: 每次 10 ⁹ CFU, 每天 1 次 第 2 ~ 12 周: 2 d 1 次 Week 1: 10 ⁹ CFU each time, once a day Weeks 2 ~ 12: once every two days.	[48]
1 g 样本在 1 mL LYH-BHI 培养基中均质, 混合液通过 70 μm 细胞过滤器过滤, 分离上清液 移植前 10 min 临时制备 1 g of samples were homogenized in 1 mL of LYH-BHI medium and filtered through 70 μm cell strainer Prepared 10 min before transplantation	每次 200 μL, 每天 1 次 200 μL each time, once a day	[78]
自体粪菌移植 Autologous fecal bacteria transplantation(aFMT)	每 2 周 1 次 Once every two weeks	[149]
结肠粘液样本在 PBS 中等比例稀释 50 g 粪便样本在 1 mL PBS 中稀释并匀质 Colon mucus samples were diluted in PBS on medium scale, 50 g of fecal sample diluted and homogenized in 1 mL PBS	第 1 天: 粘液菌每次 10 mg 第 2 ~ 3 天: 粪便混悬液每次 10 mg Day 1: mucus bacteria 10 mg each time, Day 2 ~ 3: fecal suspension 10 mg each time	[72]

3 移植途径的选择

口服灌胃或灌肠给药是啮齿动物 FMT 最为常见的移植途径(图 1),口服灌胃给药因具有给药量可控且无需麻醉的优势而更广泛采用,移植时通过弯头灌胃针将移植材料注入受体胃内,以尽可能避免与氧气的接触,保持厌氧菌活性。通常可以选择每天给予受体动物 100 ~ 200 μL 的移植材料,持续 7 ~ 14 d 以确保异体肠道微生物的成功定植^[150-151];亦可选择集中连续给药 3 d,而后每隔 1 d 给药 1 次,能达到同等的移植效果^[152-153]。不同报道中移植材料的使用量存在差异,相对标准化的建议是根据每 10 g 体重给予 0.1 mL 液体(微生物移植或生理盐水)的比例个性化给药^[108],或明确将每只受体动物每日接受的移植量控制在 200 μL (10⁸ CFU/mL)内^[112,154]。肛门给药时将涂抹石蜡

油的置入管轻插入肛门,再把加热到体温的悬浮液缓慢注入,拔下置入管后用棉签按压肛门处,并倒置动物 1 min,防止液体流出^[155-156]。研究表明,灌肠给药在坏死性结肠炎等相关肠道疾病中可以更好的发挥减轻炎症等作用^[157],研究者可根据实验目的选择适宜的移植途径。报道中亦有通过将移植材料涂抹于受体动物皮毛等基于接触共生环境中微生物接受定植的方式,但这类方式无法明确摄入量且无法实现微生物群的完整传递^[75,158-159],在结果解释上或存在疑虑。人类 FMT 往往需要多轮移植来保证定值效果,但相对无菌条件下的受体动物是否同样需要多轮移植尚无定论,通常认为当目标微生物较为复杂时,建议进行一轮以上的定植以保证定殖效率。亦或者通过荧光染色、16S rRNA 全长测序等方式对其定植情况进行监测^[160],以保证成功移植。



图 1 粪菌移植的关键步骤

Figure 1 Critical steps in fecal bacteria transplantation

4 展望

一篇关于洗涤菌群移植 (washed microbiota transplantation, WMT) 的报道^[161] 基于智能化粪菌分离系统及严格质控相关漂洗过程的概念, 通过以具体菌群数量作为精确剂量的衡量依据, 并且通过自动净化系统去除了大部分病毒及促炎物质, 在量化和质控移植材料、提高治疗安全性等方面将未来 FMT 研究引入机械化精度把控时代。研究发现, 肠道微生物群产生的脂质能够进入循环并控制与微生物组成相关的表型变化, 同时能显著影响包括炎症信号在内的多种信号通路^[162], 未来肠道微生物源脂质的应用或能通过靶向特定受体调控信号通路, 实现针对性个性化治疗, 同时有效避免病原体的伴随转移。基于当前对 FMT 后微生物定植规律的不明晰, IANIRO 等^[163] 发表的一项分析供体菌株植入率与疗效关系的研究提出, 建立可预测 FMT 后菌株定植情况的机器学习模型, 能够帮助选择最匹配受体的菌群供体, 提示在未来研究中通过智能算法的广泛应用, 可以实现对 FMT 后受体肠道菌群的精准预测, 以确定最佳供体。此外, 未来若能基于机器学习等手段预测药物成分-肠道微生物-宿主间的复杂作用, 或能有效助力化学结构及调控机制网

络复杂的药物作用机制的阐释、应用思路的拓展^[164-165]

5 总结

基于当前 FMT 临床前研究的报道中实验细节的高度不一致, 亟需标准的方法学指导。本文回顾并讨论了 FMT 动物实验的关键步骤细节, 其目的在于提高实验动物、耗材及劳动力等因素的利用率, 其中部分是基于当前动物实验的报道, 其他则是综合参考了评议性文章^[166-167]。受限于回顾的文献以小鼠为目标对象, 以上提及的方法学建议或存在偏倚, 期待更多关于 FMT 临床前研究方法学建议的文章, 并最终提出“黄金标准”的方法学指导。

参 考 文 献 (References)

[1] 李晓蕾, 李地艳, 孙静. 以肠道菌群为靶向的粪菌移植法及其在畜牧业的应用潜能 [J]. 中国实验动物学报, 2019, 27 (1): 124-128.
LI X L, LI D Y, SUN J. Intestinal flora-targeted fecal microbiota transplantation and its potential applications in animal husbandry [J]. Acta Lab Anim Sci Sin, 2019, 27(1): 124-128.

[2] ZHANG L, MA X, LIU P, et al. Treatment and mechanism of fecal microbiota transplantation in mice with experimentally induced ulcerative colitis [J]. Exp Biol Med, 2021, 246(13): 1563-1575.

[3] WILMES L, COLLINS J M, O' RIORDAN K J, et al. Of

- bowels, brain and behavior: a role for the gut microbiota in psychiatric comorbidities in irritable bowel syndrome [J]. *Neurogastroenterol Motil*, 2021, 33(3): e14095.
- [4] JING Y, BAI F, WANG L, et al. Fecal microbiota transplantation exerts neuroprotective effects in a mouse spinal cord injury model by modulating the microenvironment at the lesion site [J]. *Microbiol Spectr*, 2022, 10(3): e0017722.
- [5] KIM M S, KIM Y, CHOI H, et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model [J]. *Gut*, 2020, 69(2): 283–294.
- [6] BÁRCENA C, VALDÉS-MAS R, MAYORAL P, et al. Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice [J]. *Nat Med*, 2019, 25(8): 1234–1242.
- [7] ZHANG P P, LI L L, HAN X, et al. Fecal microbiota transplantation improves metabolism and gut microbiome composition in db/db mice [J]. *Acta Pharmacol Sin*, 2020, 41(5): 678–685.
- [8] HUGENHOLTZ F, DE VOS W M. Mouse models for human intestinal microbiota research: a critical evaluation [J]. *Cell Mol Life Sci*, 2018, 75(1): 149–160.
- [9] NGUYEN T L A, VIEIRA-SILVA S, LISTON A, et al. How informative is the mouse for human gut microbiota research? [J]. *Dis Model Mech*, 2015, 8(1): 1–16.
- [10] HILDEBRAND F, NGUYEN T L, BRINKMAN B, et al. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice [J]. *Genome Biol*, 2013, 14(1): R4.
- [11] LLEAL M, SARRABAYROUSE G, WILLAMIL J, et al. A single faecal microbiota transplantation modulates the microbiome and improves clinical manifestations in a rat model of colitis [J]. *EBioMedicine*, 2019, 48: 630–641.
- [12] PARODI G, LEITE G, PIMENTEL M L, et al. The response of the rodent gut microbiome to broad-spectrum antibiotics is different in males and females [J]. *Front Microbiol*, 2022, 13: 897283.
- [13] ELANGO VAN S, BORODY T J, DAMIAN HOLSINGER R M D. Fecal microbiota transplantation reduces pathology and improves cognition in a mouse model of Alzheimer's disease [J]. *Cells*, 2022, 12(1): 119.
- [14] LEITE G, PIMENTEL M, BARLOW G M, et al. Age and the aging process significantly alter the small bowel microbiome [J]. *Cell Rep*, 2021, 36(13): 109765.
- [15] LEITE G, PIMENTEL M, BARLOW G M, et al. The small bowel microbiome changes significantly with age and aspects of the ageing process [J]. *Microb Cell*, 2022, 9(1): 21–23.
- [16] LI Y, CAO W, GAO N L, et al. Consistent alterations of human fecal microbes after transplantation into germ-free mice [J]. *Genomics Proteomics Bioinformatics*, 2022, 20(2): 382–393.
- [17] VICENTINI F A, SZAMOSI J C, ROSSI L, et al. Colitis-associated microbiota drives changes in behaviour in male mice in the absence of inflammation [J]. *Brain Behav Immun*, 2022, 102: 266–278.
- [18] LUCZYNSKI P, WHELAN S O, O'SULLIVAN C, et al. Adult microbiota-deficient mice have distinct dendritic morphological changes: differential effects in the amygdala and hippocampus [J]. *Eur J Neurosci*, 2016, 44(9): 2654–2666.
- [19] UZBAY T. Germ-free animal experiments in the gut microbiota studies [J]. *Curr Opin Pharmacol*, 2019, 49: 6–10.
- [20] KENNEDY E A, KING K Y, BALDRIDGE M T. Mouse microbiota models: comparing germ-free mice and antibiotics treatment as tools for modifying gut bacteria [J]. *Front Physiol*, 2018, 9: 1534.
- [21] LYTE J M, PROCTOR A, PHILLIPS G J, et al. Altered Schaedler flora mice: a defined microbiota animal model to study the microbiota-gut-brain axis [J]. *Behav Brain Res*, 2019, 356: 221–226.
- [22] HOCES D, LAN J, SUN W, et al. Metabolic reconstitution of germ-free mice by a gnotobiotic microbiota varies over the circadian cycle [J]. *PLoS Biol*, 2022, 20(9): e3001743.
- [23] ÅHLGREN J, VOIKAR V. Housing mice in the individually ventilated or open cages-Does it matter for behavioral phenotype? [J]. *Genes Brain Behav*, 2019, 18(7): e12564.
- [24] ZHANG Q, LI T, NIU J, et al. Inhibitory effects of antibiotic-induced gut microbiota depletion on acute itch behavior in mice [J]. *Brain Res Bull*, 2022, 190: 50–61.
- [25] PODLESNY D, DURDEVIC M, PARAMSOTHY S, et al. Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics [J]. *Cell Rep Med*, 2022, 3(8): 100711.
- [26] LAVELLE A, HOFFMANN T W, PHAM H P, et al. Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host [J]. *Microbiome*, 2019, 7(1): 111.
- [27] ZHANG N, LIU J, CHEN Z, et al. Integrated analysis of the alterations in gut microbiota and metabolites of mice induced after long-term intervention with different antibiotics [J]. *Front Microbiol*, 2022, 13: 832915.
- [28] CABRAL D J, PENUMUTCHU S, REINHART E M, et al. Microbial metabolism modulates antibiotic susceptibility within the murine gut microbiome [J]. *Cell Metab*, 2019, 30(4): 800–823.
- [29] HUANG C, FENG S, HUO F, et al. Effects of four antibiotics on the diversity of the intestinal microbiota [J]. *Microbiol Spectr*, 2022, 10(2): e0190421.
- [30] KAPPEL B A, ANGELIS L D, PUETZ A, et al. Antibiotic-induced gut microbiota depletion exacerbates host hypercholesterolemia [J]. *Pharmacol Res*, 2023, 187: 106570.
- [31] SUN N, HU H, WANG F, et al. Antibiotic-induced microbiome depletion in adult mice disrupts blood-brain barrier and facilitates brain infiltration of monocytes after bone-marrow transplantation [J]. *Brain Behav Immun*, 2021, 92: 102–114.
- [32] DAHIYA D, NIGAM P S. Antibiotic-therapy-induced gut dysbiosis affecting gut microbiota-brain axis and cognition: restoration by intake of probiotics and synbiotics [J]. *Int J Mol Sci*, 2023, 24(4): 3074.

- [33] TOCHITANI S, IKENO T, ITO T, et al. Administration of non-absorbable antibiotics to pregnant mice to perturb the maternal gut microbiota is associated with alterations in offspring behavior [J]. PLoS One, 2016, 11(1): e0138293.
- [34] XU Z, DONG X, YANG K, et al. Association of Adherent-invasive *Escherichia coli* with severe Gut Mucosal dysbiosis in Chinese population with Crohn's disease [J]. Gut Microbes, 2021, 13(1): 1994833.
- [35] ZHAO Z X, YUAN X, CUI Y Y, et al. Melatonin mitigates oxazolone-induced colitis in microbiota-dependent manner [J]. Front Immunol, 2021, 12: 783806.
- [36] ZHU W, HONG Y, LI Y, et al. Microbial and transcriptomic profiling reveals diet-related alterations of metabolism in metabolic disordered mice [J]. Front Nutr, 2022, 9: 923377.
- [37] RODRIGUEZ-PALACIOS A, KHORETONENKO M V, ILIC S. Institutional protocols for the oral administration (gavage) of chemicals and microscopic microbial communities to mice: Analytical consensus [J]. Exp Biol Med, 2019, 244(6): 459–470.
- [38] ZHANG X, ZHAO S, SONG X, et al. Inhibition effect of glycyrrhiza polysaccharide (GCP) on tumor growth through regulation of the gut microbiota composition [J]. J Pharmacol Sci, 2018, 137(4): 324–332.
- [39] ZHANG S, ZENG L, MA J, et al. Gut Prevotellaceae-GABAergic septohippocampal pathway mediates spatial memory impairment in high-fat diet-fed ovariectomized mice [J]. Neurobiol Dis, 2023, 177: 105993.
- [40] PARKER A, ROMANO S, ANSORGE R, et al. Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain [J]. Microbiome, 2022, 10(1): 68.
- [41] ZHANG S L, MAO Y Q, ZHANG Z Y, et al. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer [J]. Theranostics, 2021, 11(9): 4155–4170.
- [42] FAN X, MAI C, ZUO L, et al. Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury *via* increasing the gut microbiota *Lactobacillus johnsonii* and regulating macrophage anti-inflammatory activity in mice [J]. Acta Pharm Sin B, 2023, 13(3): 1164–1179.
- [43] XU X, ZHUO L, ZHANG L, et al. Dexmedetomidine alleviates host ADHD-like behaviors by reshaping the gut microbiota and reducing gut-brain inflammation [J]. Psychiatry Res, 2023, 323: 115172.
- [44] LIANG H, SONG H, ZHANG X, et al. Metformin attenuated sepsis-related liver injury by modulating gut microbiota [J]. Emerg Microbes Infect, 2022, 11(1): 815–828.
- [45] LEI Y, TANG L, LIU S, et al. *Parabacteroides* produces acetate to alleviate heparanase-exacerbated acute pancreatitis through reducing neutrophil infiltration [J]. Microbiome, 2021, 9(1): 115.
- [46] TANG X, WANG W, HONG G, et al. Gut microbiota-mediated lysophosphatidylcholine generation promotes colitis in intestinal epithelium-specific Fut2 deficiency [J]. J Biomed Sci, 2021, 28(1): 20.
- [47] HU J, DENG F, ZHAO B, et al. *Lactobacillus murinus* alleviate intestinal ischemia/reperfusion injury through promoting the release of interleukin-10 from M2 macrophages via Toll-like receptor 2 signaling [J]. Microbiome, 2022, 10(1): 38.
- [48] MA J, LIU Z, GAO X, et al. Gut microbiota remodeling improves natural aging-related disorders through *Akkermansia muciniphila* and its derived acetic acid [J]. Pharmacol Res, 2023, 189: 106687.
- [49] RIZVI Z A, DALAL R, SADHU S, et al. High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity [J]. Sci Adv, 2021, 7(37): eabg5016.
- [50] HOU Q, HUANG J, ZHAO L, et al. Dietary genistein increases microbiota-derived short chain fatty acid levels, modulates homeostasis of the aging gut, and extends healthspan and lifespan [J]. Pharmacol Res, 2023, 188: 106676.
- [51] GE X, HE X, LIU J, et al. Amelioration of type 2 diabetes by the novel 6, 8-guanidyl luteolin quinone-chromium coordination via biochemical mechanisms and gut microbiota interaction [J]. J Adv Res, 2023, 46: 173–188.
- [52] GU Y, WANG C, QIN X, et al. *Saccharomyces boulardii*, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota [J]. Pharmacol Res, 2022, 181: 106291.
- [53] ZHAO Q, YU J, ZHOU H, et al. Intestinal dysbiosis exacerbates the pathogenesis of psoriasis-like phenotype through changes in fatty acid metabolism [J]. Signal Transduct Target Ther, 2023, 8(1): 40.
- [54] ZENG X, LI X, LI X, et al. Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation [J]. Blood, 2023, 141(14): 1691–1707.
- [55] LI H Y, HUANG S Y, ZHOU D D, et al. Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis [J]. J Adv Res, 2023, 52: 59–72.
- [56] YAN M, MAN S, LIANG Y, et al. Diosgenin alleviates nonalcoholic steatohepatitis through affecting liver-gut circulation [J]. Pharmacol Res, 2023, 187: 106621.
- [57] HAN Q, WANG J, LI W, et al. Androgen-induced gut dysbiosis disrupts glucolipid metabolism and endocrinal functions in polycystic ovary syndrome [J]. Microbiome, 2021, 9(1): 101.
- [58] DONG S, ZHU M, WANG K, et al. Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism [J]. Pharmacol Res, 2021, 171: 105767.
- [59] HU H, SHAO W, LIU Q, et al. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion [J]. Nat Commun, 2022, 13(1): 252.
- [60] KIM E S, YOON B H, LEE S M, et al. Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q/TNF-

- related protein 9 genetic deficiency [J]. *Exp Mol Med*, 2022, 54(2): 103–114.
- [61] MODICA M D, GARGARI G, REGONDI V, et al. Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer [J]. *Cancer Res*, 2021, 81(8): 2195–2206.
- [62] XU K, GUO Y, WANG Y, et al. Decreased Enterobacteriaceae translocation due to gut microbiota remodeling mediates the alleviation of premature aging by a high-fat diet [J]. *Aging Cell*, 2023, 22(2): e13760.
- [63] KIM S, LEE J Y, SHIN S G, et al. ESRRA (estrogen related receptor alpha) is a critical regulator of intestinal homeostasis through activation of autophagic flux via gut microbiota [J]. *Autophagy*, 2021, 17(10): 2856–2875.
- [64] HOU Y F, SHAN C, ZHUANG S Y, et al. Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease [J]. *Microbiome*, 2021, 9(1): 34.
- [65] BRUSILOVSKY M, BAO R, ROCHMAN M, et al. Host-microbiota interactions in the esophagus during homeostasis and allergic inflammation [J]. *Gastroenterology*, 2022, 162(2): 521–534.
- [66] LITTMANN E R, LEE J J, DENNY J E, et al. Host immunity modulates the efficacy of microbiota transplantation for treatment of *Clostridioides difficile* infection [J]. *Nat Commun*, 2021, 12(1): 755.
- [67] MESSAOUDENE M, PIDGEON R, RICHARD C, et al. A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota [J]. *Cancer Discov*, 2022, 12(4): 1070–1087.
- [68] ZHONG W, WU K, LONG Z, et al. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF- κ B-IL6-STAT3 axis [J]. *Microbiome*, 2022, 10(1): 94.
- [69] VAN DEN BERG F F, VAN DALEN D, HYOJU S K, et al. Western-type diet influences mortality from necrotising pancreatitis and demonstrates a central role for butyrate [J]. *Gut*, 2021, 70(5): 915–927.
- [70] WU C, ZHAO Y, ZHANG Y, et al. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients [J]. *J Adv Res*, 2022, 37: 197–208.
- [71] LIU Y, ZHONG X, LIN S, et al. *Limosilactobacillus reuteri* and caffeoylquinic acid synergistically promote adipose browning and ameliorate obesity-associated disorders [J]. *Microbiome*, 2022, 10(1): 226.
- [72] STRATI F, PUJOLASSOS M, BURRELLO C, et al. Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models [J]. *Microbiome*, 2021, 9(1): 39.
- [73] JIANG L, HONG Y, XIAO P, et al. The role of fecal microbiota in liver toxicity induced by perfluorooctane sulfonate in male and female mice [J]. *Environ Health Perspect*, 2022, 130(6): 67009.
- [74] XIAO W, SU J, GAO X, et al. The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids [J]. *Microbiome*, 2022, 10(1): 62.
- [75] KIM K H, CHUNG Y, HUH J W, et al. Gut microbiota of the young ameliorates physical fitness of the aged in mice [J]. *Microbiome*, 2022, 10(1): 238.
- [76] WANG X, WANG Z, CAO J, et al. Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation [J]. *Microbiome*, 2023, 11(1): 17.
- [77] ZHANG Y, FAN Q, HOU Y, et al. *Bacteroides* species differentially modulate depression-like behavior via gut-brain metabolic signaling [J]. *Brain Behav Immun*, 2022, 102: 11–22.
- [78] CONG J, WU D, DAI H, et al. Interleukin-37 exacerbates experimental colitis in an intestinal microbiome-dependent fashion [J]. *Theranostics*, 2022, 12(11): 5204–5219.
- [79] PAN W, ZHAO J, WU J, et al. Dimethyl itaconate ameliorates cognitive impairment induced by a high-fat diet via the gut-brain axis in mice [J]. *Microbiome*, 2023, 11(1): 30.
- [80] SHANG J, ZHANG Y, GUO R, et al. Gut microbiome analysis can be used as a noninvasive diagnostic tool and plays an essential role in the onset of membranous nephropathy [J]. *Adv Sci*, 2022, 9(28): e2201581.
- [81] CHEN Y, LIU Y, WANG Y, et al. Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPAR α -CYP4X1 axis in colonic macrophages [J]. *J Exp Clin Cancer Res*, 2022, 41(1): 1.
- [82] CHEN G, PENG Y, HUANG Y, et al. Fluoride induced leaky gut and bloom of *Erysipelatoclostridium ramosum* mediate the exacerbation of obesity in high-fat-diet fed mice [J]. *J Adv Res*, 2023, 50: 35–54.
- [83] GAO A, SU J, LIU R, et al. Sexual dimorphism in glucose metabolism is shaped by androgen-driven gut microbiome [J]. *Nat Commun*, 2021, 12(1): 7080.
- [84] CHOI B S, DANIEL N, HOUE V P, et al. Feeding diversified protein sources exacerbates hepatic insulin resistance via increased gut microbial branched-chain fatty acids and mTORC1 signaling in obese mice [J]. *Nat Commun*, 2021, 12(1): 3377.
- [85] ALGHETAA H, MOHAMMED A, ZHOU J, et al. Resveratrol-mediated attenuation of superantigen-driven acute respiratory distress syndrome is mediated by microbiota in the lungs and gut [J]. *Pharmacol Res*, 2021, 167: 105548.
- [86] LAM K C, ARAYA R E, HUANG A, et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment [J]. *Cell*, 2021, 184(21): 5338–5356.
- [87] LIU Z, LI C, LIU M, et al. The Low-density lipoprotein Receptor-related protein 6 pathway in the treatment of intestinal barrier dysfunction induced by hypoxia and intestinal microbiota

- through the Wnt/ β -catenin pathway [J]. Int J Biol Sci, 2022, 18(11): 4469–4481.
- [88] ZHENG H, XU P, JIANG Q, et al. Depletion of acetate-producing bacteria from the gut microbiota facilitates cognitive impairment through the gut-brain neural mechanism in diabetic mice [J]. Microbiome, 2021, 9(1): 145.
- [89] LU J, CHEN P P, ZHANG J X, et al. GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPK α activity [J]. Theranostics, 2021, 11(10): 4728–4742.
- [90] SOTO-PANTOJA D R, GABER M, ARNONE A A, et al. Diet alters entero-mammary signaling to regulate the breast microbiome and tumorigenesis [J]. Cancer Res, 2021, 81(14): 3890–3904.
- [91] BLAKE S J, JAMES J, RYAN F J, et al. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota [J]. Cell Rep Med, 2021, 2(12): 100464.
- [92] JI S K, YAN H, JIANG T, et al. Preparing the gut with antibiotics enhances gut microbiota reprogramming efficiency by promoting xenomicrobiota colonization [J]. Front Microbiol, 2017, 8: 1208.
- [93] LI M, QIAN W, YU L, et al. Multi-time-point fecal sampling in human and mouse reveals the formation of new homeostasis in gut microbiota after bowel cleansing [J]. Microorganisms, 2022, 10(12): 2317.
- [94] 陈启仪, 田宏亮, 杨波, 等. 不同肠道准备方式对菌群移植疗效及安全性的影响 [J]. 中华胃肠外科杂志, 2020, 23(1): 48–55.
- CHEN Q Y, TIAN H L, YANG B, et al. Effect of intestinal preparation on the efficacy and safety of fecal microbiota transplantation treatment [J]. Chin J Gastrointest Surg, 2020, 23(1): 48–55.
- [95] ZHENG P, LI Y, WU J, et al. Erratum: perturbed microbial ecology in myasthenia gravis: evidence from the gut microbiome and fecal metabolome [J]. Adv Sci, 2020, 7(10): 2001296.
- [96] DE WOUTERS D' OPLINTER A, RASTELLI M, VAN HUL M, et al. Gut microbes participate in food preference alterations during obesity [J]. Gut Microbes, 2021, 13(1): 1959242.
- [97] ZHU J, REN H, ZHONG H, et al. An expanded gene catalog of mouse gut metagenomes [J]. mSphere, 2021, 6(1): e01119–e01120.
- [98] FISCHER A W, CANNON B, NEDERGAARD J. Optimal housing temperatures for mice to mimic the thermal environment of humans: An experimental study [J]. Mol Metab, 2018, 7: 161–170.
- [99] GINTING R P, LEE J M, LEE M W. The influence of ambient temperature on adipose tissue homeostasis, metabolic diseases and cancers [J]. Cells, 2023, 12(6): 881.
- [100] GUPTA Y, ERNST A L, VOROBYEV A, et al. Impact of diet and host genetics on the murine intestinal mycobioime [J]. Nat Commun, 2023, 14(1): 834.
- [101] CHAIX A, DEOTA S, BHARDWAJ R, et al. Sex- and age-dependent outcomes of 9-hour time-restricted feeding of a Western high-fat high-sucrose diet in C57BL/6J mice [J]. Cell Rep, 2021, 36(7): 109543.
- [102] MATSUMOTO S, REN L, IIGO M, et al. Mimicking seasonal changes in light-dark cycle and ambient temperature modulates gut microbiome in mice under the same dietary regimen [J]. PLoS One, 2023, 18(2): e0278013.
- [103] HASAN N, YANG H. Factors affecting the composition of the gut microbiota, and its modulation [J]. Peer J, 2019, 7: e7502.
- [104] ZHANG Y, LI Y, BARBER A F, et al. The microbiome stabilizes circadian rhythms in the gut [J]. Proc Natl Acad Sci U S A, 2023, 120(5): e2217532120.
- [105] WOODIE L N, LUO Y, WAYNE M J, et al. Restricted feeding for 9 h in the active period partially abrogates the detrimental metabolic effects of a Western diet with liquid sugar consumption in mice [J]. Metabolism, 2018, 82: 1–13.
- [106] ZHENG Y, DING Y, XU M, et al. Gut microbiota contributes to host defense against *Klebsiella pneumoniae*-induced liver abscess [J]. J Inflamm Res, 2021, 14: 5215–5225.
- [107] YU F, JIANG R, HAN W, et al. Gut microbiota transplantation from db/db mice induces diabetes-like phenotypes and alterations in Hippo signaling in pseudo germ-free mice [J]. Aging, 2020, 12(23): 24156–24167.
- [108] ZHANG N, ZHANG Y, WANG Z, et al. Regular fecal microbiota transplantation to senescence accelerated mouse-prone 8 (SAMP8) mice delayed the aging of locomotor and exploration ability by rejuvenating the gut microbiota [J]. Front Aging Neurosci, 2022, 14: 991157.
- [109] ZHONG Z, CHEN W, GAO H, et al. Fecal microbiota transplantation exerts a protective role in MPTP-induced Parkinson's disease via the TLR4/PI3K/AKT/NF- κ B pathway stimulated by α -synuclein [J]. Neurochem Res, 2021, 46(11): 3050–3058.
- [110] ZHAO L, HUANG Y, LU L, et al. Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats [J]. Microbiome, 2018, 6(1): 107.
- [111] LI N, ZUO B, HUANG S, et al. Spatial heterogeneity of bacterial colonization across different gut segments following inter-species microbiota transplantation [J]. Microbiome, 2020, 8(1): 161.
- [112] ERICSSON A C, GAGLIARDI J, BOUHAN D, et al. The influence of caging, bedding, and diet on the composition of the microbiota in different regions of the mouse gut [J]. Sci Rep, 2018, 8(1): 4065.
- [113] WANG S, HUANG M, YOU X, et al. Gut microbiota mediates the anti-obesity effect of calorie restriction in mice [J]. Sci Rep, 2018, 8(1): 13037.
- [114] BELLALI S, LAGIER J C, RAOULT D, et al. Among live and dead bacteria, the optimization of sample collection and processing remains essential in recovering gut microbiota components [J]. Front Microbiol, 2019, 10: 1606.
- [115] TAKAHASHI M, ISHIKAWA D, SASAKI T, et al. Faecal

- freezing preservation period influences colonization ability for faecal microbiota transplantation [J]. J Appl Microbiol, 2019, 126(3): 973–984.
- [116] CHEN A, HU Y, ZHANG Y, et al. Cryopreservation of stool samples altered the microbial viability quantitatively and compositionally [J]. Arch Microbiol, 2022, 204(9): 557.
- [117] ALLEGRETTI J R, ELLIOTT R J, LADHA A, et al. Stool processing speed and storage duration do not impact the clinical effectiveness of fecal microbiota transplantation [J]. Gut Microbes, 2020, 11(6): 1806–1808.
- [118] CHOO J M, ROGERS G B. Gut microbiota transplantation for colonization of germ-free mice [J]. STAR Protoc, 2021, 2(3): 100610.
- [119] YANG J, SUI X, WEN C, et al. A hemocompatible cryoprotectant inspired by freezing-tolerant plants [J]. Colloids Surf B Biointerfaces, 2019, 176: 106–114.
- [120] BURZ S D, ABRAHAM A L, FONSECA F, et al. A guide for *ex vivo* handling and storage of stool samples intended for fecal microbiota transplantation [J]. Sci Rep, 2019, 9(1): 8897.
- [121] BENSCH H M, TOLF C, WALDENSTRÖM J, et al. Freeze-drying can replace cold-chains for transport and storage of fecal microbiome samples [J]. PeerJ, 2022, 10: e13095.
- [122] MOOSSAVI S, ENGEN P A, GHANBARI R, et al. Assessment of the impact of different fecal storage protocols on the microbiota diversity and composition: a pilot study [J]. BMC Microbiol, 2019, 19(1): 145.
- [123] ROMANO K A, DILL-MCFARLAND K A, KASAHARA K, et al. Fecal Aliquot Straw Technique (FAST) allows for easy and reproducible subsampling; assessing interpersonal variation in trimethylamine-N-oxide (TMAO) accumulation [J]. Microbiome, 2018, 6(1): 91.
- [124] ZHANG F, ZHANG X, YU J, et al. The gut microbiota confers the lipid-lowering effect of bitter melon (*Momordica charantia* L.) in high-fat diet (HFD)-Induced hyperlipidemic mice [J]. Biomed Pharmacother, 2020, 131: 110667.
- [125] ZHONG Y, XIAO Y, GAO J, et al. Curcumin improves insulin sensitivity in high-fat diet-fed mice through gut microbiota [J]. Nutr Metab, 2022, 19(1): 76.
- [126] QUARANTA G, FANCELLO G, IANIRO G, et al. Laboratory handling practice for faecal microbiota transplantation [J]. J Appl Microbiol, 2020, 128(3): 893–898.
- [127] ZHANG M, HONG Y, WU W, et al. Pivotal role of the gut microbiota in congenital insensitivity to pain with anhidrosis [J]. Psychopharmacology, 2021, 238(11): 3131–3142.
- [128] YUAN X, ZHOU F, WANG H, et al. Systemic antibiotics increase microbiota pathogenicity and oral bone loss [J]. Int J Oral Sci, 2023, 15(1): 4.
- [129] KIM J H, KIM K, KIM W. Gut microbiota restoration through fecal microbiota transplantation: a new atopic dermatitis therapy [J]. Exp Mol Med, 2021, 53(5): 907–916.
- [130] WU Z, HUANG S, LI T, et al. Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis [J]. Microbiome, 2021, 9(1): 184.
- [131] BERMUDEZ-MARTIN P, BECKER J A J, CARMELLO N, et al. The microbial metabolite p-Cresol induces autistic-like behaviors in mice by remodeling the gut microbiota [J]. Microbiome, 2021, 9(1): 157.
- [132] HILTUNEN H, HANANI H, LUOTO R, et al. Preterm infant meconium microbiota transplant induces growth failure, inflammatory activation, and metabolic disturbances in germ-free mice [J]. Cell Rep Med, 2021, 2(11): 100447.
- [133] KIM E, PAIK D, RAMIREZ R N, et al. Maternal gut bacteria drive intestinal inflammation in offspring with neurodevelopmental disorders by altering the chromatin landscape of CD4⁺ T cells [J]. Immunity, 2022, 55(1): 145–158.
- [134] SHARMA V K, PRATEEKSHA, GUPTA S C, et al. *Cinnamomum verum*-derived bioactives-functionalized gold nanoparticles for prevention of obesity through gut microbiota reshaping [J]. Mater Today Bio, 2022, 13: 100204.
- [135] ZHANG X, COKER O O, CHU E S, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites [J]. Gut, 2021, 70(4): 761–774.
- [136] CHENG W, WANG Z, XIONG Y, et al. N-(3-oxododecanoyl)-homoserine lactone disrupts intestinal barrier and induces systemic inflammation through perturbing gut microbiome in mice [J]. Sci Total Environ, 2021, 778: 146347.
- [137] FANG Y, ZHANG J, ZHU S, et al. Berberine ameliorates ovariectomy-induced anxiety-like behaviors by enrichment in equol generating gut microbiota [J]. Pharmacol Res, 2021, 165: 105439.
- [138] YI W, JI Y, GAO H, et al. Effects of urban particulate matter on gut microbiome and partial schizophrenia-like symptoms in mice: Evidence from shotgun metagenomic and metabolomic profiling [J]. Sci Total Environ, 2023, 857(1): 159305.
- [139] BECKMANN L, KÜNSTNER A, FRESCHI M L, et al. Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect [J]. Pharmacol Res, 2021, 170: 105724.
- [140] HUANG J, LIU D, WANG Y, et al. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy [J]. Gut, 2022, 71(4): 734–745.
- [141] ZHU W, ROMANO K A, LI L, et al. Gut microbes impact stroke severity via the trimethylamine N-oxide pathway [J]. Cell Host Microbe, 2021, 29(7): 1199–1208.
- [142] AHMED B A, ONG F J, BARRA N G, et al. Lower brown adipose tissue activity is associated with non-alcoholic fatty liver disease but not changes in the gut microbiota [J]. Cell Rep Med, 2021, 2(9): 100397.
- [143] KHALYFA A, ERICSSON A, QIAO Z, et al. Circulating exosomes and gut microbiome induced insulin resistance in mice

- exposed to intermittent hypoxia: Effects of physical activity [J]. *EBioMedicine*, 2021, 64: 103208.
- [144] LUO L, LUO J, CAI Y, et al. Inulin-type fructans change the gut microbiota and prevent the development of diabetic nephropathy [J]. *Pharmacol Res*, 2022, 183: 106367.
- [145] ZHAO Z, NING J, BAO X Q, et al. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis [J]. *Microbiome*, 2021, 9(1): 226.
- [146] RENGA G, NUNZI E, PARIANO M, et al. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite [J]. *J Immunother Cancer*, 2022, 10(3): e003725.
- [147] GUO P, YANG X, GUO X, et al. Dietary fish oil improves autistic behaviors and gut homeostasis by altering the gut microbial composition in a mouse model of fragile X syndrome [J]. *Brain Behav Immun*, 2023, 110: 140–151.
- [148] YU M, ALIMUJIANG M, HU L, et al. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver [J]. *Int J Biol Sci*, 2021, 17(7): 1693–1707.
- [149] RINOTT E, YOUNGSTER I, YASKOLKA MEIR A, et al. Effects of diet-modulated autologous fecal microbiota transplantation on weight regain [J]. *Gastroenterology*, 2021, 160(1): 158–173.
- [150] ZHANG X Y, CHEN J, YI K, et al. Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity [J]. *Gut Microbes*, 2020, 12(1): 1–18.
- [151] ZHANG W, ZOU G, LI B, et al. Fecal microbiota transplantation (FMT) alleviates experimental colitis in mice by gut microbiota regulation [J]. *J Microbiol Biotechnol*, 2020, 30(8): 1132–1141.
- [152] ZHAO C, BAO L, ZHAO Y, et al. A fiber-enriched diet alleviates *Staphylococcus aureus*-induced mastitis by activating the HDAC3-mediated antimicrobial program in macrophages via butyrate production in mice [J]. *PLoS Pathog*, 2023, 19(1): e1011108.
- [153] ZHANG Y, HUANG R, CHENG M, et al. Gut microbiota from NLRP3-deficient mice ameliorates depressive-like behaviors by regulating astrocyte dysfunction via circHIPK2 [J]. *Microbiome*, 2019, 7(1): 116.
- [154] ZHANG Y W, CAO M M, LI Y J, et al. Fecal microbiota transplantation ameliorates bone loss in mice with ovariectomy-induced osteoporosis via modulating gut microbiota and metabolic function [J]. *J Orthop Translat*, 2022, 37: 46–60.
- [155] ZHANG J, CHEN Z, YU H, et al. Anti-aging effects of a functional food via the action of gut microbiota and metabolites in aging mice [J]. *Aging*, 2021, 13(13): 17880–17900.
- [156] ZHOU J, ZHOU Z, JI P, et al. Effect of fecal microbiota transplantation on experimental colitis in mice [J]. *Exp Ther Med*, 2019, 17(4): 2581–2586.
- [157] LIU J, MIYAKE H, ZHU H, et al. Fecal microbiota transplantation by enema reduces intestinal injury in experimental necrotizing enterocolitis [J]. *J Pediatr Surg*, 2020, 55(6): 1094–1098.
- [158] YU X, FU X, WU X, et al. Metformin alleviates neuroinflammation following intracerebral hemorrhage in mice by regulating microglia/macrophage phenotype in a gut microbiota-dependent manner [J]. *Front Cell Neurosci*, 2021, 15: 789471.
- [159] ERICSSON A C, FRANKLIN C L. Manipulating the gut microbiota: methods and challenges [J]. *ILAR J*, 2015, 56(2): 205–217.
- [160] JOHNSON J S, SPAKOWICZ D J, HONG B Y, et al. Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis [J]. *Nat Commun*, 2019, 10(1): 5029.
- [161] ZHANG T, LU G, ZHAO Z, et al. Washed microbiota transplantation *vs.* manual fecal microbiota transplantation: clinical findings, animal studies and *in vitro* screening [J]. *Protein Cell*, 2020, 11(4): 251–266.
- [162] CARNEIRO P V, MONTENEGRO N A, LANA A, et al. Lipids from gut microbiota: pursuing a personalized treatment [J]. *Trends Mol Med*, 2022, 28(8): 631–643.
- [163] IANIRO G, PUNÇOCHÁR M, KARCHER N, et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases [J]. *Nat Med*, 2022, 28(9): 1913–1923.
- [164] QIU F, LU W, YE S, et al. Berberine promotes induction of immunological tolerance to an allograft via downregulating memory CD8⁺ T-cells through altering the gut microbiota [J]. *Front Immunol*, 2021, 12: 646831.
- [165] WANG Y, ZHANG J, XU L, et al. Modified Gegen Qinlian Decoction regulates treg/Th17 balance to ameliorate DSS-induced acute experimental colitis in mice by altering the gut microbiota [J]. *Front Pharmacol*, 2021, 12: 756978.
- [166] ANIAM C B, et al. Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols [J]. *Gut Microbes*, 2021, 13(1): 1979878.
- [167] VBOKOLIYA S C, DORSETT Y, PANIER H, et al. Procedures for fecal microbiota transplantation in murine microbiome studies [J]. *Front Cell Infect Microbiol*, 2021, 11: 711055.